COVID-19

AstraZeneca vaccine: Paris prosecutor’s office is considering three complaints after death, including one in Toulouse

The Department of Public Health of the Paris Prosecutor’s Office, competent to investigate highly complex health product-related offenses, now leads on the fact of “manslaughter” a preliminary investigation has been initiated, following the filing of complaints in Toulouse, Paris and Nantes, as well as preliminary investigations by the local prosecutor’s office.

According to the Paris prosecutor’s office, the plaintiffs “in particular the question of the causal role AstraZeneca vaccinethat were introduced to their loved one before dying“.”We went to the local prosecutor’s office to expedite our complaints, to do an autopsy, and then ask them to transfer the case to Paris.“, – explained to Agence France Presse Me Etienne Bouittin, the lawyer who has had the complaints.

A 38-year-old woman who died in Toulouse and a medical student in Nantes.

In Toulouse, 38 year old social worker saw her health deteriorate shortly after the first injection, and died on March 29 of a cerebral thrombosis. His family filed a complaint on April 2. Me Boyten says he has received about fifteen human deaths in France after being vaccinated with AstraZeneca, the vast majority of people between the ages of “Up to 60 years old”.

In Nantes, 26-year-old medical student died suddenly at home from a thrombosis (clot) on March 18, a few days after the vaccine was administered. Autopsy results must be known “within a few days”, according to Me Boyttin.

The use of the AstraZeneca vaccine has been restricted in most European Union countries due to the very rare cases of thrombosis it can cause. Denmark no longer uses it.

In France, since March 19, the vaccine is no longer given to persons under 55 years of age. For this category of people who have already received a dose of this vaccine, the Supreme Health Authority has recommended a second dose with Pfizer-BioNTech or Moderna. A scientific committee dedicated to the rare and atypical thrombosis seen after Covid-19 vaccination was formed last week by ANSM, a pharmaceutical agency, to help clarify the mechanisms.

Back to top button